Skip to main content

Table 2 Acalabrutinib (ACP-196) for solid tumors

From: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Agents Diseases Phase NCT
ACP-196 Glioblastoma multiforme Phase 1/2 NCT02586857
ACP-196
Pembrolizumab
Urothelial carcinoma Phase 2 NCT02351739
ACP-196
Pembrolizumab
Non-small-cell lung cancer Phase 2 NCT02448303
ACP-196
Pembrolizumab
Head and neck
Squamous cell carcinoma
Phase 2 NCT02454179
ACP-196
Pembrolizumab
Ovarian cancer Phase 2 NCT02537444
ACP-196
Pembrolizumab
Pancreatic cancer Phase 2 NCT02362048
ACP-196
Nab-paclitaxel
Gemcitabine
Pancreatic cancer Phase 2 NCT02570711